Marketing authorizations have already been granted in the relevant territory, according to a press release sent to the Budapest Business Journal. According to the agreement, Richter will be obligated to pay sales-related royalties to L.D. Collins after the productʼs launch.

“Cyclogest is considered a useful addition to our existing fertility portfolio,” said Gábor Orbán, CEO of Gedeon Richter. “Being a responsible player in the pharmaceutical universe, we are aware of the importance of the productiveness of the female population and we are committed to addressing women’s needs.”

Cyclogest pessaries contain 400 mg of progesterone, which is a naturally occurring progestogen. The pessaries prepare the lining of the uterus to be as receptive as possible to the embryo and are therefore critical in supporting the luteal phase as part of assisted reproductive technology, according to the press release.